View Future GrowthHerbal Dispatch 과거 순이익 실적과거 기준 점검 0/6Herbal Dispatch은 연평균 15.3%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 8.8%의 비율로 증가했습니다. 매출은 연평균 63.4%의 비율로 증가했습니다.핵심 정보15.27%순이익 성장률35.24%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률7.33%매출 성장률63.39%자기자본이익률-60.66%순이익률-15.19%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트Reported Earnings • Aug 23Second quarter 2024 earnings released: EPS: CA$0.001 (vs CA$0.006 loss in 2Q 2023)Second quarter 2024 results: EPS: CA$0.001 (up from CA$0.006 loss in 2Q 2023). Revenue: CA$3.65m (up 215% from 2Q 2023). Net income: CA$58.6k (up CA$460.2k from 2Q 2023). Profit margin: 1.6% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue.Reported Earnings • May 02Full year 2023 earnings released: CA$0.029 loss per share (vs CA$0.092 loss in FY 2022)Full year 2023 results: CA$0.029 loss per share (improved from CA$0.092 loss in FY 2022). Revenue: CA$4.74m (up CA$4.43m from FY 2022). Net loss: CA$2.07m (loss narrowed 55% from FY 2022).Reported Earnings • Nov 25Third quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 3Q 2022)Third quarter 2023 results: CA$0.001 loss per share (in line with 3Q 2022). Revenue: CA$1.17m (up CA$1.07m from 3Q 2022). Net loss: CA$533.0k (loss narrowed 32% from 3Q 2022).Reported Earnings • Aug 31Second quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.003 loss in 2Q 2022)Second quarter 2023 results: CA$0.001 loss per share (improved from CA$0.003 loss in 2Q 2022). Revenue: CA$1.16m (up CA$1.15m from 2Q 2022). Net loss: CA$401.7k (loss narrowed 71% from 2Q 2022).Reported Earnings • Jun 02First quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 1Q 2022)First quarter 2023 results: CA$0.001 loss per share (in line with 1Q 2022). Net loss: CA$685.8k (loss widened 23% from 1Q 2022).Reported Earnings • May 01Full year 2022 earnings released: CA$0.009 loss per share (vs CA$0.006 loss in FY 2021)Full year 2022 results: CA$0.009 loss per share (further deteriorated from CA$0.006 loss in FY 2021). Net loss: CA$4.62m (loss widened 93% from FY 2021).모든 업데이트 보기Recent updatesBoard Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Drew Malcolm was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Oct 21Herbal Dispatch Inc. announced that it has received CAD 2.078211 million in fundingOn October 20, 2025, Herbal Dispatch Inc. closed the transaction. The company issued 41,564,220 units at a price of CAD 0.05 per Unit for gross proceeds of up to CAD 2,078,211. In connection with the closing of the private placement, the company incurred finder's fees to qualified arm’s length finders (the “finders”) as follows: (a) an aggregate cash payment of CAD 103,495; and (b) the issuance of 599,900 Warrants. Such finder’s fees were paid only to Finders who executed finder’s fee agreements with the Company and who successfully introduced investors that participated in the Private Placement. The transaction included participation from new investors Roderick W. Law Corporation, EPC Holdings Ltd., and ADH Holdings Ltd., for an aggregate of 6,814,420 Units, representing approximately 16.39% of the total Units permitted to be subscribed for under the Private Placement.공시 • Jul 30Herbal Dispatch Inc. announced that it expects to receive CAD 1 million in fundingHerbal Dispatch Inc. announced a non-brokered private placement of up to 20,000,000 units at a price of CAD 0.05 per Unit for gross proceeds of up to CAD 1,000,000. Each Unit shall consist of one common share and one-half common share purchase warrant with each Warrant transferable and exercisable for one common share at a price of CAD 0.08 per share for a period of 24 months after the closing date. The Private Placement shall be completed on a best-efforts basis from eligible purchasers that shall be restricted to accredited investors or other investors meeting exemption requirements for a non-brokered private placement. The closing of the Private Placement is expected to occur before August 29, 2025, and is subject to receipt of all necessary regulatory approvals, including the approval of the CSE. Should the Private Placement be oversubscribed, the Company reserves the right to accept additional funds, subject to the approval of the Canadian Securities Exchange (“CSE”). All securities issued pursuant to the Private Placement will be subject to a four month hold period in accordance with applicable Canadian securities laws.공시 • Apr 08Herbal Dispatch Inc., Annual General Meeting, Jun 10, 2025Herbal Dispatch Inc., Annual General Meeting, Jun 10, 2025.공시 • Mar 25Herbal Dispatch Inc. announced that it has received CAD 0.6 million in fundingHerbal Dispatch Inc. announced that it will receive CAD 600,000 in a round of funding on March 25, 2025. The company will also issue 3,000,000 warrants in the transaction. Each warrants are convertible to common stock of the company at an exercise price of $0.065 per share. The warrants will expire on March 19, 2029. The company has received debt in the transaction which incurs interest rate of 18% p.a. and is repayable in equal monthly instalments of $29,955. The warrants carry a hold period of four months. The company has incurred a closing fee of $12,000 in the transaction. The transaction included participation from Philip Campbell representing one of the Lenders, and via a wholly owned company, and provided $100,000 of the debt and will receive 500,100 of the warrants issued.공시 • Oct 09Herbal Dispatch Inc., Annual General Meeting, Dec 16, 2024Herbal Dispatch Inc., Annual General Meeting, Dec 16, 2024.Reported Earnings • Aug 23Second quarter 2024 earnings released: EPS: CA$0.001 (vs CA$0.006 loss in 2Q 2023)Second quarter 2024 results: EPS: CA$0.001 (up from CA$0.006 loss in 2Q 2023). Revenue: CA$3.65m (up 215% from 2Q 2023). Net income: CA$58.6k (up CA$460.2k from 2Q 2023). Profit margin: 1.6% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue.New Risk • May 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$472k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$472k free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (€2.76m market cap, or US$2.98m). Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (CA$5.7m revenue, or US$4.2m).Board Change • May 13Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Drew Malcolm was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • May 10Herbal Dispatch Inc. Announces Board ChangesHerbal Dispatch Inc. announces that effective May 8, 2024, Jeremy South has resigned as a Director and Chairman of the Company. The Company is grateful to Mr. South for his contribution throughout the yearsand wishes him all the best in his future endeavors. The Honourable Herb Dhaliwal, a Director the Company, has agreed to be appointed as interim Chairman of the Company until a permanent successoris appointed.Reported Earnings • May 02Full year 2023 earnings released: CA$0.029 loss per share (vs CA$0.092 loss in FY 2022)Full year 2023 results: CA$0.029 loss per share (improved from CA$0.092 loss in FY 2022). Revenue: CA$4.74m (up CA$4.43m from FY 2022). Net loss: CA$2.07m (loss narrowed 55% from FY 2022).공시 • Mar 21Herbal Dispatch Inc. announced that it expects to receive CAD 1 million in fundingHerbal Dispatch Inc. announced on best-effort basis a non-brokered private placement of up to 20,000,000 units at a price of CAD 0.05 per unit for the gross proceeds of CAD 1,000,000 on March 20, 2024. Each Unit shall consist of one common share and one common share warrant with each Warrant exercisable for one common share at a price of CAD 0.06 per share for a period of 24 months after the closing date. Should the Private Placement be oversubscribed, the Company reserves the right to accept additional funds, subject to the approval of the Canadian Securities Exchange and is also subjected to regulatory approvals. The closing of the Private Placement is expected to occur before April 5, 2024. All securities issued pursuant to the private placement will be subject to a four month hold period in accordance with applicable Canadian securities laws.공시 • Dec 16Herbal Dispatch Inc. announced that it expects to receive CAD 0.938 million in fundingHerbal Dispatch Inc. announced that it has issued an unsecured convertible debenture in the principal amount of CAD 938,000 for gross proceeds of CAD 938,000 on December 15, 2023. The transaction included participation from directors. The company also amended the terms of a convertible debenture in the principal amount of CAD 438,000 owing to another director of the company. The debenture bears interest at an annual rate of 14% per annum, payable monthly, and matures on January 31, 2025. The transaction is subject to the approval of the Canadian Securities Exchange. The debenture will also be convertible, at the holder’s option into common shares of the company at a price of CAD 0.05 per share, and at the it’s election, during any period where the trading price of the it’s common shares is CAD 0.10 or greater for a period of 20 consecutive trading days. The company issued principal amount of CAD 500,000 to a director of the company in its first tranche.Reported Earnings • Nov 25Third quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 3Q 2022)Third quarter 2023 results: CA$0.001 loss per share (in line with 3Q 2022). Revenue: CA$1.17m (up CA$1.07m from 3Q 2022). Net loss: CA$533.0k (loss narrowed 32% from 3Q 2022).공시 • Oct 07Herbal Dispatch Inc., Annual General Meeting, Dec 15, 2023Herbal Dispatch Inc., Annual General Meeting, Dec 15, 2023.Reported Earnings • Aug 31Second quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.003 loss in 2Q 2022)Second quarter 2023 results: CA$0.001 loss per share (improved from CA$0.003 loss in 2Q 2022). Revenue: CA$1.16m (up CA$1.15m from 2Q 2022). Net loss: CA$401.7k (loss narrowed 71% from 2Q 2022).Reported Earnings • Jun 02First quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 1Q 2022)First quarter 2023 results: CA$0.001 loss per share (in line with 1Q 2022). Net loss: CA$685.8k (loss widened 23% from 1Q 2022).공시 • May 27Herbal Dispatch Inc. announced that it expects to receive CAD 1 million in fundingHerbal Dispatch Inc. announced a non-brokered private placement of up to 100,000,000 units at a price of CAD 0.01 per unit for the gross proceeds of CAD 1,000,000 on May 25, 2023. Each unit consist of one common share and one common share warrant. Each warrant is exercisable for one common share at a price of CAD 0.05 per share for a period of 24 months after the closing date. All securities issued pursuant to the private placement will be subject to a four month hold period. The transaction is subject to the approval of all necessary regulatory approvals including the approval of the CSE. The transaction is expected to close on June 30, 2023.Reported Earnings • May 01Full year 2022 earnings released: CA$0.009 loss per share (vs CA$0.006 loss in FY 2021)Full year 2022 results: CA$0.009 loss per share (further deteriorated from CA$0.006 loss in FY 2021). Net loss: CA$4.62m (loss widened 93% from FY 2021).Reported Earnings • Dec 02Third quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.002 loss in 3Q 2021)Third quarter 2022 results: CA$0.001 loss per share (improved from CA$0.002 loss in 3Q 2021). Net loss: CA$778.0k (loss narrowed 7.3% from 3Q 2021).매출 및 비용 세부 내역Herbal Dispatch가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DB:HA9 매출, 비용 및 순이익 (CAD Millions)날짜매출순이익일반관리비연구개발비31 Dec 2512-24030 Sep 2510-33030 Jun 2510-33031 Mar 2511-23031 Dec 2410-33030 Sep 2410-23030 Jun 248-23031 Mar 246-23031 Dec 235-23030 Sep 233-43030 Jun 232-43031 Mar 231-53031 Dec 220-52030 Sep 220-23030 Jun 220-22031 Mar 221-23031 Dec 211-23030 Sep 211-53030 Jun 210-42031 Mar 210-52031 Dec 200-63030 Sep 200-195030 Jun 200-217031 Mar 200-237031 Dec 191-229030 Sep 19-2-1610131 Dec 183-3017131 May 1810-1411028 Feb 1811-108031 May 175-33031 May 161-210양질의 수익: HA9 은(는) 현재 수익성이 없습니다.이익 마진 증가: HA9는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: HA9는 수익성이 없지만 지난 5년 동안 연평균 15.3%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 HA9의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: HA9은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(16.1%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: HA9는 현재 수익성이 없으므로 자본 수익률이 음수(-60.66%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 00:03종가2026/05/22 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Herbal Dispatch Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Aug 23Second quarter 2024 earnings released: EPS: CA$0.001 (vs CA$0.006 loss in 2Q 2023)Second quarter 2024 results: EPS: CA$0.001 (up from CA$0.006 loss in 2Q 2023). Revenue: CA$3.65m (up 215% from 2Q 2023). Net income: CA$58.6k (up CA$460.2k from 2Q 2023). Profit margin: 1.6% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue.
Reported Earnings • May 02Full year 2023 earnings released: CA$0.029 loss per share (vs CA$0.092 loss in FY 2022)Full year 2023 results: CA$0.029 loss per share (improved from CA$0.092 loss in FY 2022). Revenue: CA$4.74m (up CA$4.43m from FY 2022). Net loss: CA$2.07m (loss narrowed 55% from FY 2022).
Reported Earnings • Nov 25Third quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 3Q 2022)Third quarter 2023 results: CA$0.001 loss per share (in line with 3Q 2022). Revenue: CA$1.17m (up CA$1.07m from 3Q 2022). Net loss: CA$533.0k (loss narrowed 32% from 3Q 2022).
Reported Earnings • Aug 31Second quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.003 loss in 2Q 2022)Second quarter 2023 results: CA$0.001 loss per share (improved from CA$0.003 loss in 2Q 2022). Revenue: CA$1.16m (up CA$1.15m from 2Q 2022). Net loss: CA$401.7k (loss narrowed 71% from 2Q 2022).
Reported Earnings • Jun 02First quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 1Q 2022)First quarter 2023 results: CA$0.001 loss per share (in line with 1Q 2022). Net loss: CA$685.8k (loss widened 23% from 1Q 2022).
Reported Earnings • May 01Full year 2022 earnings released: CA$0.009 loss per share (vs CA$0.006 loss in FY 2021)Full year 2022 results: CA$0.009 loss per share (further deteriorated from CA$0.006 loss in FY 2021). Net loss: CA$4.62m (loss widened 93% from FY 2021).
Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Drew Malcolm was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Oct 21Herbal Dispatch Inc. announced that it has received CAD 2.078211 million in fundingOn October 20, 2025, Herbal Dispatch Inc. closed the transaction. The company issued 41,564,220 units at a price of CAD 0.05 per Unit for gross proceeds of up to CAD 2,078,211. In connection with the closing of the private placement, the company incurred finder's fees to qualified arm’s length finders (the “finders”) as follows: (a) an aggregate cash payment of CAD 103,495; and (b) the issuance of 599,900 Warrants. Such finder’s fees were paid only to Finders who executed finder’s fee agreements with the Company and who successfully introduced investors that participated in the Private Placement. The transaction included participation from new investors Roderick W. Law Corporation, EPC Holdings Ltd., and ADH Holdings Ltd., for an aggregate of 6,814,420 Units, representing approximately 16.39% of the total Units permitted to be subscribed for under the Private Placement.
공시 • Jul 30Herbal Dispatch Inc. announced that it expects to receive CAD 1 million in fundingHerbal Dispatch Inc. announced a non-brokered private placement of up to 20,000,000 units at a price of CAD 0.05 per Unit for gross proceeds of up to CAD 1,000,000. Each Unit shall consist of one common share and one-half common share purchase warrant with each Warrant transferable and exercisable for one common share at a price of CAD 0.08 per share for a period of 24 months after the closing date. The Private Placement shall be completed on a best-efforts basis from eligible purchasers that shall be restricted to accredited investors or other investors meeting exemption requirements for a non-brokered private placement. The closing of the Private Placement is expected to occur before August 29, 2025, and is subject to receipt of all necessary regulatory approvals, including the approval of the CSE. Should the Private Placement be oversubscribed, the Company reserves the right to accept additional funds, subject to the approval of the Canadian Securities Exchange (“CSE”). All securities issued pursuant to the Private Placement will be subject to a four month hold period in accordance with applicable Canadian securities laws.
공시 • Apr 08Herbal Dispatch Inc., Annual General Meeting, Jun 10, 2025Herbal Dispatch Inc., Annual General Meeting, Jun 10, 2025.
공시 • Mar 25Herbal Dispatch Inc. announced that it has received CAD 0.6 million in fundingHerbal Dispatch Inc. announced that it will receive CAD 600,000 in a round of funding on March 25, 2025. The company will also issue 3,000,000 warrants in the transaction. Each warrants are convertible to common stock of the company at an exercise price of $0.065 per share. The warrants will expire on March 19, 2029. The company has received debt in the transaction which incurs interest rate of 18% p.a. and is repayable in equal monthly instalments of $29,955. The warrants carry a hold period of four months. The company has incurred a closing fee of $12,000 in the transaction. The transaction included participation from Philip Campbell representing one of the Lenders, and via a wholly owned company, and provided $100,000 of the debt and will receive 500,100 of the warrants issued.
공시 • Oct 09Herbal Dispatch Inc., Annual General Meeting, Dec 16, 2024Herbal Dispatch Inc., Annual General Meeting, Dec 16, 2024.
Reported Earnings • Aug 23Second quarter 2024 earnings released: EPS: CA$0.001 (vs CA$0.006 loss in 2Q 2023)Second quarter 2024 results: EPS: CA$0.001 (up from CA$0.006 loss in 2Q 2023). Revenue: CA$3.65m (up 215% from 2Q 2023). Net income: CA$58.6k (up CA$460.2k from 2Q 2023). Profit margin: 1.6% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue.
New Risk • May 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$472k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$472k free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (€2.76m market cap, or US$2.98m). Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (CA$5.7m revenue, or US$4.2m).
Board Change • May 13Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Drew Malcolm was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • May 10Herbal Dispatch Inc. Announces Board ChangesHerbal Dispatch Inc. announces that effective May 8, 2024, Jeremy South has resigned as a Director and Chairman of the Company. The Company is grateful to Mr. South for his contribution throughout the yearsand wishes him all the best in his future endeavors. The Honourable Herb Dhaliwal, a Director the Company, has agreed to be appointed as interim Chairman of the Company until a permanent successoris appointed.
Reported Earnings • May 02Full year 2023 earnings released: CA$0.029 loss per share (vs CA$0.092 loss in FY 2022)Full year 2023 results: CA$0.029 loss per share (improved from CA$0.092 loss in FY 2022). Revenue: CA$4.74m (up CA$4.43m from FY 2022). Net loss: CA$2.07m (loss narrowed 55% from FY 2022).
공시 • Mar 21Herbal Dispatch Inc. announced that it expects to receive CAD 1 million in fundingHerbal Dispatch Inc. announced on best-effort basis a non-brokered private placement of up to 20,000,000 units at a price of CAD 0.05 per unit for the gross proceeds of CAD 1,000,000 on March 20, 2024. Each Unit shall consist of one common share and one common share warrant with each Warrant exercisable for one common share at a price of CAD 0.06 per share for a period of 24 months after the closing date. Should the Private Placement be oversubscribed, the Company reserves the right to accept additional funds, subject to the approval of the Canadian Securities Exchange and is also subjected to regulatory approvals. The closing of the Private Placement is expected to occur before April 5, 2024. All securities issued pursuant to the private placement will be subject to a four month hold period in accordance with applicable Canadian securities laws.
공시 • Dec 16Herbal Dispatch Inc. announced that it expects to receive CAD 0.938 million in fundingHerbal Dispatch Inc. announced that it has issued an unsecured convertible debenture in the principal amount of CAD 938,000 for gross proceeds of CAD 938,000 on December 15, 2023. The transaction included participation from directors. The company also amended the terms of a convertible debenture in the principal amount of CAD 438,000 owing to another director of the company. The debenture bears interest at an annual rate of 14% per annum, payable monthly, and matures on January 31, 2025. The transaction is subject to the approval of the Canadian Securities Exchange. The debenture will also be convertible, at the holder’s option into common shares of the company at a price of CAD 0.05 per share, and at the it’s election, during any period where the trading price of the it’s common shares is CAD 0.10 or greater for a period of 20 consecutive trading days. The company issued principal amount of CAD 500,000 to a director of the company in its first tranche.
Reported Earnings • Nov 25Third quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 3Q 2022)Third quarter 2023 results: CA$0.001 loss per share (in line with 3Q 2022). Revenue: CA$1.17m (up CA$1.07m from 3Q 2022). Net loss: CA$533.0k (loss narrowed 32% from 3Q 2022).
공시 • Oct 07Herbal Dispatch Inc., Annual General Meeting, Dec 15, 2023Herbal Dispatch Inc., Annual General Meeting, Dec 15, 2023.
Reported Earnings • Aug 31Second quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.003 loss in 2Q 2022)Second quarter 2023 results: CA$0.001 loss per share (improved from CA$0.003 loss in 2Q 2022). Revenue: CA$1.16m (up CA$1.15m from 2Q 2022). Net loss: CA$401.7k (loss narrowed 71% from 2Q 2022).
Reported Earnings • Jun 02First quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 1Q 2022)First quarter 2023 results: CA$0.001 loss per share (in line with 1Q 2022). Net loss: CA$685.8k (loss widened 23% from 1Q 2022).
공시 • May 27Herbal Dispatch Inc. announced that it expects to receive CAD 1 million in fundingHerbal Dispatch Inc. announced a non-brokered private placement of up to 100,000,000 units at a price of CAD 0.01 per unit for the gross proceeds of CAD 1,000,000 on May 25, 2023. Each unit consist of one common share and one common share warrant. Each warrant is exercisable for one common share at a price of CAD 0.05 per share for a period of 24 months after the closing date. All securities issued pursuant to the private placement will be subject to a four month hold period. The transaction is subject to the approval of all necessary regulatory approvals including the approval of the CSE. The transaction is expected to close on June 30, 2023.
Reported Earnings • May 01Full year 2022 earnings released: CA$0.009 loss per share (vs CA$0.006 loss in FY 2021)Full year 2022 results: CA$0.009 loss per share (further deteriorated from CA$0.006 loss in FY 2021). Net loss: CA$4.62m (loss widened 93% from FY 2021).
Reported Earnings • Dec 02Third quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.002 loss in 3Q 2021)Third quarter 2022 results: CA$0.001 loss per share (improved from CA$0.002 loss in 3Q 2021). Net loss: CA$778.0k (loss narrowed 7.3% from 3Q 2021).